drugset / Trial / NCT05468307
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
Phase 0
Completed
26 enrolled
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with cyclophosphamide.
Timeline
- Start
- 2022-03-10
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC203 TIL | Cell therapy | 2e+08 cells | Intravenous |
| Subject | GC203 TIL | Cell therapy | 1e+10 cells | Intravenous |